

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 07:33:34 ON 13 FEB 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

TOTAL
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:33:57 ON 13 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 FEB 2007 HIGHEST RN 920588-28-9

DICTIONARY FILE UPDATES: 12 FEB 2007 HIGHEST RN 920588-28-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10821545.str



chain nodes :

14 15 16 17 18 19 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13

chain bonds :

14-15 14-26 15-16 16-17 16-18 17-19 26-27


ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-13 10-11 11-12 12-13
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-13 10-11 11-12 12-13
14-15 14-26 15-16 16-17 16-18 17-19 26-27
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:Atom 26:CLASS 27:CLASS 30:CLASS
Generic attributes :
19:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :
Node 19: Limited
C,C4
O,O1
N,N1
S,S0

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:34:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2488 TO ITERATE

80.4% PROCESSED 2000 ITERATIONS 7 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 46769 TO 52751
PROJECTED ANSWERS: 7 TO 351

L2 7 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:34:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 48986 TO ITERATE

100.0% PROCESSED 48986 ITERATIONS 196 ANSWERS
SEARCH TIME: 00.00.03

L3 196 SEA SSS FUL L1

=> s l3 and caplus/lc

53392306 CAPLUS/LC

L4 192 L3 AND CAPLUS/LC

=> s l3 not l4


L5

4 L3 NOT L4

=> d 15 1-4


L5 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 794501-55-6 REGISTRY
 ED Entered STN: 08 Dec 2004
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-3-pyridinyl-, (5S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H25 Cl N6 O3
 CI COM
 SR CA

Absolute stereochemistry.



L5 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 794501-54-5 REGISTRY
 ED Entered STN: 08 Dec 2004
 CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C19 H21 Cl N4 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L5 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 794501-52-3 REGISTRY
 ED Entered STN: 08 Dec 2004
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-4-pyridinyl-, (5S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C25 H25 Cl N6 O3
 CI COM
 SR CA

Absolute stereochemistry.





L5 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 783349-80-4 REGISTRY
 ED Entered STN: 18 Nov 2004
 CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C21 H26 Cl N5 O2
 CI COM
 SR CA

Absolute stereochemistry.



=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10821545.str



chain nodes :

14 15 16 17 18 19 26 27

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13

chain bonds :

14-15 14-26 15-16 16-17 16-18 17-19 26-27

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 7-10 8-9 8-13 10-11 11-12 12-13

L6 STRUCTURE UPLOADED

=> d

L6 HAS NO ANSWERS

L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 16

SAMPLE SEARCH INITIATED 07:37:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3364 TO ITERATE

59.5% PROCESSED 2000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 63802 TO 70758

PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L6

=> s 16 full

FULL SEARCH INITIATED 07:37:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 67865 TO ITERATE

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 07:33:34 ON 13 FEB 2007)

FILE 'REGISTRY' ENTERED AT 07:33:57 ON 13 FEB 2007

L1	STRUCTURE UPLOADED
L2	7 S L1
L3	196 S L1 FULL
L4	192 S L3 AND CAPLUS/LC
L5	4 S L3 NOT L4
L6	STRUCTURE UPLOADED
L7	0 S L6
L8	0 S L6 FULL

FILE 'CAPLUS' ENTERED AT 07:37:39 ON 13 FEB 2007

=> s l4

L9	4 L4
----	------

=> d ibib abs hitstr 1-4

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2005:115525 CAPLUS

DOCUMENT NUMBER: 143:422250

TITLE: Preparation of substituted β -carboline I κ B kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents

INVENTOR(S): Hepperle, Michael E.; Liu, Julie Fields; Soucy, Francois; Raman, Prakash; Little, Jeremy D.; Fleming, Paul E.; Reynolds, Dominic; Harriman, Geraldine C. B. Millennium Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 143 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239781	A1	20051027	US 2005-101998	20050408
AU 2005243188	A1	20051124	AU 2005-243188	20050408
CA 2561859	A1	20051124	CA 2005-2561859	20050408
WO 2005111037	A1	20051124	WO 2005-US13812	20050408

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1735311 A1 20061227 EP 2005-779267 20050408

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

PRIORITY APPLN. INFO.: US 2004-560892P P 20040409

WO 2005-US13812 W 20050408

OTHER SOURCE(S): MARPAT 143:422250

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Substituted β -carbolines I [Q = CH₂, CH-R₉; G = NR₄R₅, 3-7 membered (un)substituted heterocyclyl; R₁ = H, halo, alkyl, amino, alkylamino; R₂, R₃ = independently H, halo, C1-2 aliphatic, alkoxy, haloalkyl; R₄, each R = independently H, C1-6 aliphatic; R₅ = (un)substituted C1-6 aliphatic; R₉ = C1-3 aliphatic; and their pharmaceutically acceptable salts] were prepared as inhibitors of I κ B kinase 2 (IKK-2) for the treatment of inflammatory or immune system diseases such as rheumatoid arthritis, asthma, psoriasis,

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

RN 783349-79-1 CAPLUS

CN 4-Morpholinecarboxylic acid, 5-[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-81-5 CAPLUS


CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 783349-80-4

CMF C21 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

chronic obstructive pulmonary disease, or cancer (particularly lymphoma). E.g., coupling of (S)-4-[(S)-2-tert-butoxycarbonylamino]propyl]-6,6-dimethylmorpholine-3-carboxylic acid with 6-chloro-4-methyl-9H- β -carbolin-8-ylamine, Boc-deprotection, and acylation of amine salt with 2-methylnicotinic acid. Selected β -carbolines I displayed IC₅₀ < 100 nM for inhibition of I κ B kinase in in vitro and cell-based assays. I

were selective for inhibiting IKK-2 as opposed to IKK-1.

IT 783349-59-7P 783349-60-0P 783349-79-1P

783349-81-5P 783349-82-6P 783349-83-7P

783349-84-8P 783349-90-6P 783350-38-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted β -carboline I κ B kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)

RN 783349-59-7 CAPLUS

CN 4-Morpholinecarboxylic acid, 3-[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 783349-60-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-4-morpholinylmethyl-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 783349-82-6 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 783349-83-7 CAPLUS

CN Carbamic acid, [(1S)-2-[(5S)-5-[[6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 783349-84-8 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-


Absolute stereochemistry.



● HCl



RN 783349-90-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783350-38-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-amino-3-methylbutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-28-0 CAPLUS
CN 4-Morpholinecarboxamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-N-(3-pyridinylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-29-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-N-(6-methyl-9H-pyrido[3,4-b]indol-8-yl)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 794501-53-4P 868058-28-0P 868058-29-1P
868058-30-4P 868058-31-5P 868058-32-6P
868058-33-7P 868058-34-8P 868058-35-9P
868058-36-0P 868058-37-1P 868058-38-2P
868058-39-3P 868058-40-6P 868058-41-7P
868058-42-8P 868058-43-9P 868058-44-0P
868058-45-1P 868058-46-2P 868058-47-3P
868058-48-4P 868058-49-5P 868058-50-8P
868058-51-9P 868058-52-0P 868058-53-1P
868058-54-2P 868058-55-3P 868058-56-4P
868058-57-5P 868058-58-6P 868058-59-7P
868058-60-0P 868058-61-1P 868058-62-2P
868058-63-3P 868058-64-4P 868058-65-5P
868058-66-6P 868058-67-7P 868058-68-8P
868058-69-9P 868058-70-2P 868058-71-3P
868058-72-4P 868058-73-5P 868058-74-6P
868058-75-7P 868058-76-8P 868058-77-9P
868058-78-0P 868058-79-1P 868058-80-4P
868058-81-5P 868058-82-6P 868058-83-7P
868058-84-8P 868058-85-9P 868058-86-0P
868058-87-1P 868058-88-2P 868058-89-3P
868058-90-6P 868058-91-7P 868058-92-8P
868058-94-0P 868058-95-1P 868058-96-2P
868058-97-3P 868058-98-4P 868058-99-5P
868059-00-1P 868059-01-2P 868059-02-3P
868059-03-4P 868059-04-5P 868059-05-6P
868059-06-7P 868059-07-8P 868059-08-9P
868059-09-0P 868059-10-3P 868059-11-4P
868059-12-5P 868059-13-6P 868059-14-7P
868059-15-8P 868059-16-9P 868059-17-0P
868059-18-1P 868059-19-2P 868059-20-5P
868059-21-6P 868059-22-7P 868059-23-8P
868059-24-9P 868059-25-0P 868059-26-1P
868059-27-2P 868059-28-3P 868059-29-4P
868059-30-7P 868059-31-8P 868059-32-9P
868059-33-0P 868059-34-1P 868059-35-2P
868059-36-3P 868059-37-4P 868059-38-5P
868059-39-6P 868059-40-9P 868059-41-0P
868059-42-1P 868059-43-2P 868059-44-3P
868059-45-4P 868059-46-5P 868059-47-6P
868140-14-1P 868140-17-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Invention compound; preparation of substituted -carboline IB kinase

2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)


RN 794501-53-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,2-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-30-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(3S)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-31-5 CAPLUS
CN D-Proline, 1-[[[5S]-5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-32-6 CAPLUS
CN 3-Morpholinecarboxamide,
N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-
6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 868058-33-7 CAPLUS
CN 3-Morpholinecarboxamide,
N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-
6,6-dimethyl-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 868058-34-8 CAPLUS
CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-
yl]amino]carbonyl]-N-cyclohexyl-2,2-dimethyl-, (5S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 868058-35-9 CAPLUS
CN 3-Morpholinecarboxamide,
N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-
6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 868058-36-0 CAPLUS
CN 3-Morpholinecarboxamide,
N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-
6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 868058-37-1 CAPLUS
CN 3-Morpholinecarboxamide,
N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-
6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 868058-38-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-
dimethyl-4-[(1R)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 868058-39-3 CAPLUS
CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-
yl]amino]carbonyl]-N-ethyl-N,2,2-trimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 868058-40-6 CAPLUS
CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-(1,1-dimethylethyl)-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-41-7 CAPLUS
CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-methoxy-N,2,2-trimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-45-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-4-methyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-46-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3-hydroxy-3-methyl-1-pyrrolidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 868058-42-8 CAPLUS
CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-N-[(3-methyl-4-pyridinyl)methyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-43-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[(2R)-2-[(methylamino)carbonyl]-1-pyrrolidinyl]-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-44-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-N-(4-oxocyclohexyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-47-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4,4-difluoro-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-48-4 CAPLUS
CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-(6-methoxy-3-pyridinyl)-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-49-5 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(3-methyl-5-isoxazolyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-50-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 868058-53-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-(4,5-dihydro-4-methyl-5-oxo-1H-tetrazol-1-yl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-54-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-55-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[3,3-dimethyl-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 868058-51-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(4-oxo-1-piperidinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-52-0 CAPLUS
CN 4-Piperidineacetic acid, 1-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-56-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-(3-methyl-2-oxo-1-imidazolidinyl)-1-piperidinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-57-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 868058-58-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-difluoro-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-59-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(5S)-5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-60-0 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-ethyl-2,2-dimethyl-N-(phenylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 868058-63-3 CAPLUS
CN D-Proline, 1-[[[(5S)-5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-64-4 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-N-(4-methyl-1-piperazinyl)-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868058-65-5 CAPLUS
CN 4-Morpholineacetamide, N-(cis-4-(aminocarbonyl)cyclohexyl)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 868058-61-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-methyl-3-oxo-1-piperazinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-62-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(3-oxo-1-piperazinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 868058-66-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,4-dihydro-1(2H)-quinolinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-67-7 CAPLUS
CN Carbamic acid, [1-[[[(3R)-3-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-4-morpholinyl]acetyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-68-8 CAPLUS
CN 4-Morpholineacetamide, 5-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl-2,2-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-69-9 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[(5S)-5-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl-2,2-dimethyl-4-morpholinyl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 868058-72-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2-hydroxyethyl)amino]carbonyl-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-73-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-difluoro-1-pyrrolidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-70-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(tetrahydro-1,4-oxazepin-4(5H)-yl)ethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-71-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[(5S)-5-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl-2,2-dimethyl-4-morpholinyl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 868058-74-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-75-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2-hydroxyethyl)amino]carbonyl-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-76-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-difluoro-1-pyrrolidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-77-9 CAPLUS
 CN 1-Piperazinecarboxylic acid,
 4-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-
 8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-78-0 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-
 yl)amino]carbonyl]-2,2-dimethyl-N-1-piperidinyl-, (5S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 868058-79-1 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-
 yl)amino]carbonyl]-2,2-dimethyl-N-4-piperidinyl-, (5S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 868058-80-4 CAPLUS
 CN Glycine,
 N-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-
 2,2-dimethyl-4-morpholinyl]acetyl]-N-methyl-, ethyl ester (9CI) (CA
 INDEX
 NAME)

Absolute stereochemistry.




RN 868058-81-5 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-
 yl)amino]carbonyl]-N-(6-methoxy-3-pyridinyl)-2,2-dimethyl-, (5R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-82-6 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-
 dimethyl-4-[2-oxo-2-[4-(trifluoromethyl)-1-piperidinyl]ethyl]-, (3S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-83-7 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-
 yl)amino]carbonyl]-2,2-dimethyl-N-pyrazinyl-, (5S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 868058-84-8 CAPLUS
 CN 4-Morpholineacetamide, N-(1-acetyl-4-piperidinyl)-5-[[[(6-chloro-9H-
 pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 868058-85-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(4-thiomorpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-86-0 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-(4-(acetylamino)-1-piperidinyl)-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-89-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperazinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-90-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(4-(1-pyrrolidinylcarbonyl)-1-piperidinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-87-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-(4-(2-amino-2-oxoethyl)-1-piperidinyl)-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-88-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-(1-hydroxy-1-methylethyl)-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-91-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[(3aR,4S,7R,7aR)-octahydro-4-methyl-4,7-epoxy-2H-isoindol-2-yl]-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-92-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-ethynyl-4-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-94-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-95-1 CAPLUS
CN 4-Morpholinecarboxamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-[1-(methylsulfonyl)-4-piperidinyl]-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 868058-98-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-99-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(3R)-3-hydroxy-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868058-96-2 CAPLUS
CN 4-Piperidineacetic acid, 1-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868058-97-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-(3-(aminocarbonyl)-1-piperidinyl)-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 868059-00-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-dimethyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-01-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2S,6S)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-02-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3-(diethylamino)carbonyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-03-4 CAPLUS
CN 3-Morpholinecarboxamide, N-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[4-[(methylsulfonyl)amino]-1-piperidinyl]-2-oxoethyl]-, (3S)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-04-5 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-2,2-dimethyl-N-2-pyridinyl-, (5R)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-07-8 CAPLUS
CN 3-Morpholinecarboxamide, N-[(6-chloro-7-hydroxy-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-08-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[(2R)-2-(aminocarbonyl)-1-pyrrolidinyl]-2-oxoethyl]-N-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-05-6 CAPLUS
CN 3-Morpholinecarboxamide, N-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2S,6R)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-06-7 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-[4-(aminocarbonyl)-1-piperidinyl]-2-oxoethyl]-N-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-09-0 CAPLUS
CN 3-Morpholinecarboxamide, N-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-[(3,3-difluoro-1-pyrrolidinyl)carbonyl]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-10-3 CAPLUS
CN 3-Morpholinecarboxamide, N-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[3-hydroxy-1-azetidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-11-4 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(2-furanylmethyl)-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-12-5 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6R)-2,6-dimethyl-4-morpholinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-13-6 CAPLUS
 CN 4-Morpholineacetamide, N-[1-(aminocarbonyl)cyclohexyl]-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-16-9 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(2,2-dimethyl-4-morpholinyl)-, (5S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-17-0 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-cyclohexyl-N-ethyl-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-14-7 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-oxo-2,8-diazaspiro[4.5]dec-8-yl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-15-8 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[2-(4-amino-1-piperidinyl)-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-18-1 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(2,2-dimethyl-4-morpholinyl)-, (5S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-19-2 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4,4-dimethyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 868059-20-5 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(4-phenyl-1-piperidinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-21-6 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-ethyl-N-(2-hydroxyethyl)-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-22-7 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-(2-furanylmethyl)-N,2,2-trimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-23-8 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,6S)-2,6-dimethyl-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-24-9 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-[(ethylamino)carbonyl]-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-25-0 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[[[5S)-5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-26-1 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-27-2 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-[4-(1-pyrrolidinylsulfonyl)-1-piperazinyl]ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-28-3 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-ethyl-2,2-dimethyl-N-(4-pyridinylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 868059-29-4 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-3-(2,2,6,6-tetramethyl-4-piperidinyl)propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-30-7 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(1,1-dioxido-4-thiomorpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-31-8 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-[(3-fluoro-4-pyridinyl)methyl]-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 868059-34-1 CAPLUS
 CN 2-Aziridinecarboxylic acid, 1-[[[(5S)-5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 868059-35-2 CAPLUS
 CN 4-Piperidineacetic acid, 1-[[[(5S)-5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-4-hydroxy-α,α-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 868059-36-3 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[4-hydroxy-4-(trifluoromethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 868059-32-9 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-ethyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-33-0 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-4-phenyl-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 868059-37-4 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(2-oxo-1,3,8-triazaspiro[4.5]dec-8-yl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-38-5 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(2,2,6,6-tetramethyl-4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-39-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(dimethylamino)sulfonyl]-1-piperazinyl]-2-oxoethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-40-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[2-(4-benzoyl-1-piperazinyl)-2-oxoethyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-41-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-[(5-methyl-1,3,4-oxadiazol-2-yl)-1-piperidinyl]-2-oxoethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-42-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-dimethyl-4-[(methylsulfonyl)amino]-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-43-2 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(3-methyl-5-isothiazolyl)-, (5R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-44-3 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N,N-diethyl-2,2-dimethyl-, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-45-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-46-5 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-1H-indol-5-yl-2,2-dimethyl-, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868059-47-6 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(2-pyridinylmethyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 868140-14-1 CAPLUS
CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-(4-hydroxy-4-methylcyclohexyl)-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-03-1 CAPLUS
CN 4-Morpholineacetic acid, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 783348-43-6P 783348-54-9P 783348-55-0P
783348-57-2P 783348-58-3P 783348-59-4P
783348-61-8P 783348-62-9P 783348-76-5P
783348-78-7P 783348-80-1P 783348-81-2P
783348-82-3P 783348-84-5P 783348-85-6P
783348-86-7P 783348-87-8P 783348-88-9P
783348-89-0P 783348-90-3P 783348-91-4P
783348-92-5P 783348-93-6P 783348-94-7P
783348-95-8P 783348-97-0P 783348-98-1P
783348-99-2P 783349-00-8P 783349-01-9P
783349-02-0P 783349-04-2P 783349-09-7P
783349-10-0P 783349-11-1P 783349-12-2P
783349-13-3P 783349-14-4P 783349-16-6P
783349-17-7P 783349-18-8P 783349-19-9P
783349-20-2P 783349-21-3P 783349-22-4P
783349-23-5P 783349-24-6P 783349-25-7P
783349-26-8P 783349-27-9P 783349-28-0P
783349-29-1P 783349-30-4P 783349-31-5P
783349-32-6P 783349-34-0P 783349-35-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compound; preparation of substituted β -carboline IxK kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)



RN 868140-17-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2-[(4-[(dimethylamino)carbonyl]cyclohexyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 783348-96-9P 783349-03-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(invention compound; preparation of substituted β -carboline IxK kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)

RN 783348-96-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminobutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 783348-43-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4,6,6-trimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-54-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-55-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-pyrrolidinylmethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 783348-57-2 CAPLUS


L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-58-3 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-59-4 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(trifluoroacetyl)amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-78-7 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetyl amino)propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 783348-80-1 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(methylsulfonyl)amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 783348-61-8 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2R)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-62-9 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-76-5 CAPLUS

L9 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 783348-81-2 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]amino]propyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-82-3 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-84-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[4-morpholinylcarbonyl]amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-85-6 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-[[[(2S)-1-acetyl-2-pyrrolidinyl]carbonyl]amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-86-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[5-methyl-3-isoxazolyl]carbonyl]amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-87-8 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-[(2-amino-2-methyl-1-oxopropyl)amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-88-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[[methylamino]carbonyl]amino]propyl]-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-89-0 CAPLUS
CN Carbanic acid, [(1S)-2-[(5S)-5-[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-90-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[[2,4-dimethyl-3-pyridinyl]carbonyl]amino]propyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-91-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(pyrazinyl)carbonyl]amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-92-5 CAPLUS
CN 3,4-Pyridinedicarboxamide, N4-[(1S)-2-[(5S)-5-[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-N3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-93-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(4-methyl-3-pyrimidinyl)carbonyl]amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-97-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-98-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-94-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(4-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-95-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-99-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[(tetrahydro-3-furanyl)carbonyl]amino]butyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-00-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-01-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetylamino)propyl]-N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-02-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-(2-methyl-3-pyridinyl)carbonylamino]propyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-10-0 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 783349-11-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-04-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2R)-2-(1-pyrrolidinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-09-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-(2-methyl-3-pyridinyl)carbonylamino]propyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-12-2 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-13-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-14-4 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 783349-16-6 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-19-9 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(2-hydroxyethyl)-N,2,2-trimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-20-2 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-4-pyridinyl-, monohydrochloride, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 783349-17-7 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-18-8 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 783349-21-3 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-22-4 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 783349-23-5 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-24-6 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N,N,2,2-tetramethyl-, (5S)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 783349-25-7 CAPLUS

CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 783349-26-8 CAPLUS


CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-27-9 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[[[(5S)-5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 783349-28-0 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,2-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 783349-29-1 CAPLUS

CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-N-(trans-4-hydroxycyclohexyl)-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 783349-30-4 CAPLUS


CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 783349-31-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(1-hydroxy-1-methylethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-32-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2-oxo-1-pyrrolidinyl)ethyl]-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-94-0 CAPLUS
CN 4-Morpholinecarboxamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-3-pyridinyl-, monohydrochloride, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 783349-95-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(3,3-dimethyl-4-oxo-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2004:902377 CAPLUS
DOCUMENT NUMBER: 141:379803
TITLE: Preparation of substituted β -carboline I κ B kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents
INVENTOR(S): Hepperle, Michael E.; Liu, Julie Fields; Soucy, Francois; Ye, Yingchun; Murray, Robert S.; Prakash, Raman; Little, Jeremy D.; Castro, Alfredo;
Mazdiyasni, Hormoz; Fleming, Paul E.; Reynolds, Dominic
PATENT ASSIGNEE(S): Millenium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 197 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092167	A1	20041028	WO 2004-US11080	20040409
WO 2004092167	AS	20060105		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004230952	A1	20041028	AU 2004-230952	20040409
CA 2521300	A1	20041028	CA 2004-2521300	20040409
US 2004235839	A1	20041125	US 2004-821545	20040409
EP 1611134	A1	20060104	EP 2004-759390	20040409
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,			
HR				
BR 2004009263	A	20060328	BR 2004-9263	20040409
CN 1802375	A	20060712	CN 2004-80016017	20040409
JP 2006522824	T	20061005	JP 2006-509889	20040409
NO 2005004598	A	20051027	NO 2005-4598	20051006
PRIORITY APPLN. INFO.:			US 2003-461468P	P 20030409
			WO 2004-US11080	W 20040409

OTHER SOURCE(S): MARPAT 141:379803
GI



AB Substituted β -carbolines I [A = (un)substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuran, cyclohexyl, cyclopentyl, thiomorpholinyl; R1 = H, halo, alkyl, amino, cyano, alkylamino, dialkylamino, alkoxy, aminocarbonyl, trifluoroacetyl amino, aminomethyl; R2 = H, halo, alkyl, F3C; R3 = H, halo, alkyl, haloalkyl, alkoxy, hydroxy, amino, cyano, alkylamino, dialkylamino] such as II are prepared as inhibitors of I κ B kinase 2 (IKK-2) for the treatment of inflammatory or immune system diseases such as rheumatoid arthritis, asthma, psoriasis, chronic obstructive pulmonary disease, or cancer (particularly lymphoma). E.g., cyclcondensation of 6-fluorotryptamine hydrochloride and glyoxalic acid monohydrate, decarboxylation of the product in acid followed by neutralization, oxidation with air in refluxing xylenes, chlorination with N-chlorosuccinimide in HCl solution, nitration with sodium nitrate and trifluoroacetic acid, nucleophilic aromatic substitution of the fluoride moiety with sodium methoxide, reduction of the nitro group with palladium and hydrogen, and acylation of the amine with 2-methylnicotinic acid and EDCI in pyridine yields II. Comps. in which ring A is either a 2-substituted-3-pyridinyl moiety or a 4-substituted-5-pyrimidinyl moiety are better inhibitors of IKK-2 than the corresponding unsubstituted heterocycle-containing

comps. in which A is a 4,6,6-trisubstituted-3-morpholinyl moiety are the most effective of those comps. in which ring A is a morpholinyl moiety (no data).
IT 783349-59-7p 783349-60-0P 783349-79-1P
783349-81-5P 783349-82-6P 783349-83-7P
783349-84-8P 783349-90-6P 783350-38-9P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted β -carboline I κ B kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)

RN 783349-59-7 CAPLUS
CN 4-Morpholinecarboxylic acid, 3-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L9 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
b]indol-8-yl]-6,6-dimethyl-, (3S)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 783349-80-4
CMF C21 H26 Cl N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 783349-82-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 783349-60-0 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[(3S)-3-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-4-morpholinyl]methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-79-1 CAPLUS
CN 4-Morpholinecarboxylic acid, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 783349-81-5 CAPLUS
CN 3-Morpholinecarboxamide, 4-[[[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-


RN 783349-83-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[[(5S)-5-[[[(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-84-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 783349-90-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 783350-38-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-amino-3-methylbutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 783348-96-9P 783349-03-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(invention compound; preparation of substituted β -carboline Ix kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)
RN 783348-96-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminobutyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-54-9 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783348-55-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-pyrrolidinylmethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-57-2 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 783349-03-1 CAPLUS
CN 4-Morpholinecarboxylic acid, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 783348-43-6P 783348-54-9P 783348-55-0P
783348-57-2P 783348-58-3P 783348-59-4P
783348-61-8P 783348-62-9P 783348-76-5P
783348-78-7P 783348-80-1P 783348-81-2P
783348-82-3P 783348-84-5P 783348-85-6P
783348-86-7P 783348-87-8P 783348-88-9P
783348-89-0P 783348-90-3P 783348-91-4P
783348-92-5P 783348-93-6P 783348-94-7P
783348-95-8P 783348-97-0P 783348-98-1P
783348-99-2P 783349-00-8P 783349-01-9P
783349-02-0P 783349-04-2P 783349-09-7P
783349-10-0P 783349-11-1P 783349-12-2P
783349-13-3P 783349-14-4P 783349-16-6P
783349-17-7P 783349-18-8P 783349-19-9P
783349-20-2P 783349-21-3P 783349-22-4P
783349-23-5P 783349-24-6P 783349-25-7P
783349-26-8P 783349-27-9P 783349-28-0P
783349-29-1P 783349-30-4P 783349-31-5P
783349-32-6P 783349-94-0P 783349-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(invention compound; preparation of substituted β -carboline Ix kinase 2 (IKK-2) inhibitors as potential antiinflammatory, immunomodulatory, or anticancer agents)
RN 783348-43-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4,6,6-trimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-58-3 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-59-4 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-61-8 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-62-9 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-76-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(trifluoroacetyl)amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-78-7 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetamino)propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-80-1 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(methylsulfonyl)amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-81-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[[[4,6-dimethyl-5-pyrimidinyl]carbonyl]amino]propyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-82-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-84-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(4-morpholinyl)carbonyl]amino]propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-85-6 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-[[[(2S)-1-acetyl-2-pyrrolidinyl]carbonyl]amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-86-7 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(5-methyl-3-isoxazolyl)carbonyl]amino]propyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-87-8 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2S)-2-[(2-amino-2-methyl-1-oxopropyl)amino]propyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-88-9 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(methylamino)carbonyl]amino]propyl-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-89-0 CAPLUS
 CN Carbamic acid, [(1S)-2-[(5S)-5-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-90-3 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-[(2,4-dimethyl-3-pyridinyl)carbonyl]amino]propyl-, 6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-91-4 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(pyrazinyl)carbonyl]amino]propyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-92-5 CAPLUS
 CN 3,4-Pyridinedicarboxamide, N4-[(1S)-2-[(5S)-5-[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-4-morpholinyl]-1-methylethyl-, N3-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-93-6 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(4-methyl-5-pyrimidinyl)carbonyl]amino]propyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-94-7 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(4-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-95-8 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(3R)-1,2,3,4-tetrahydro-3-isoquinolinyl]methyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-99-2 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[(tetrahydro-3-furanyl)carbonyl]amino]butyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-00-8 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-4-methyl-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-97-0 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783348-98-1 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-3-methyl-2-[(2-methyl-3-pyridinyl)carbonyl]amino]butyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-01-9 CAPLUS
 CN 3-Morpholinecarboxamide, 4-[(2S)-2-(acetylamino)propyl]-N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-02-0 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-4-fluoro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonyl]amino]propyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-04-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-09-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-pyrrolidinylmethyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-12-2 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2S)-2-aminopropyl]-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-13-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[(2R)-2-aminopropyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-10-0 CAPLUS
CN 3-Morpholinecarboxamide, 4-(2-aminoethyl)-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-11-1 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2S)-2-aminopropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-14-4 CAPLUS
CN 3-Morpholinecarboxamide, 4-[(2R)-2-amino-3-phenylpropyl]-N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 783349-16-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[(2S)-2-[(2-methyl-3-pyridinyl)carbonylamino]butyl]-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 783349-17-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-oxo-2-(1-piperidinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-18-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-morpholinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 783349-21-3 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-22-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxymethyl)-1-piperidinyl]-2-oxoethyl]-6,6-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-19-9 CAPLUS
CN 4-Morpholinecarboxamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N-(2-hydroxyethyl)-N,2,2-trimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-20-2 CAPLUS
CN 4-Morpholinecarboxamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-N-4-pyridinyl-, monohydrochloride, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 783349-23-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-hydroxy-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-24-6 CAPLUS
CN 4-Morpholinecarboxamide, 5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-N,N,2,2-tetramethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-25-7 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-6,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-26-8 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-27-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[[(5S)-5-[[[6-chloro-9H-pyrido[3,4-b]indol-8-yl]amino]carbonyl]-2,2-dimethyl-4-morpholinyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-28-0 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2,2-dimethyl-4-morpholinyl)-2-oxoethyl]-6,6-dimethyl-, dihydrochloride, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 783349-29-1 CAPLUS
CN 4-Morpholinecarboxamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)aminocarbonyl]-N-(trans-4-hydroxycyclohexyl)-2,2-dimethyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-30-4 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-[(2R,5R)-2,5-dimethyl-1-pyrrolidinyl]-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-31-5 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(4-(1-hydroxy-1-methylethyl)-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 783349-32-6 CAPLUS
CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(2-oxo-2-(2-oxo-1-pyrrolidinyl)ethyl)-6,6-dimethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 783349-94-0 CAPLUS
 CN 4-Morpholineacetamide, 5-[[[(6-chloro-9H-pyrido[3,4-b]indol-8-yl)amino]carbonyl]-2,2-dimethyl-N-3-pyridinyl-, monohydrochloride, (5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



• HCl

RN 783349-95-1 CAPLUS
 CN 3-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)-4-[2-(3,3-dimethyl-4-oxo-1-piperidinyl)-2-oxoethyl]-6,6-dimethyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


ACCESSION NUMBER: 2003:485903 CAPLUS
 DOCUMENT NUMBER: 139:207080
 TITLE: Novel IKK inhibitors: β -carboline
 AUTHOR(S): Castro, Alfredo C.; Dang, Luan C.; Soucy, Francois; Grenier, Louis; Mazdyassni, Hormoz; Hottelet, Maria; Parent, Lana; Pien, Christine; Palombella, Vito; Adams, Julian
 CORPORATE SOURCE: Millennium Pharmaceuticals Inc., Cambridge, MA, 02139, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(14), 2419-2422
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:207080

AB Inhibitors of I κ B kinase (IKK) have long been sought as specific regulators of NF- κ B. A screening effort of the endogenous IKK complex allowed us to identify 5-bromo-6-methoxy- β -carboline as a nonspecific IKK inhibitor. Optimization of this β -carboline natural product derivative resulted in a novel class of selective IKK inhibitors


with IC₅₀s in the nanomolar range. In addition, we show that one of these β -carboline analogs inhibits the phosphorylation of I κ B α and subsequent activation of NF- κ B in whole cells, as well as blocking TNF- α release in LPS-challenged mice.

IT 590398-98-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation and structure-activity relationship of β -carbolines as novel IKK inhibitors)

RN 590398-98-4 CAPLUS
 CN 4-Morpholinecarboxamide, N-(6-chloro-9H-pyrido[3,4-b]indol-8-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

ACCESSION NUMBER: 1989:95590 CAPLUS
 DOCUMENT NUMBER: 110:95590
 TITLE: 11-Aminovinburnine derivatives with brain-protecting properties
 AUTHOR(S): Akendengue, Blandine; Uriac, Philippe; Huet, Jean
 CORPORATE SOURCE: Lab. Chim. Pharm., UER Med., Rennes, 35043, Fr.
 SOURCE: European Journal of Medicinal Chemistry (1987), 22(6), 511-20
 CODEN: EJMCA5; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 OTHER SOURCE(S): CASREACT 110:95590



AB 11-Aminoeburnamonine derivs. (amides, amino amides, urea, carbamates) e.g.


I (R = Ac, Bz, piperidinoacetyl, etc.) were prepared from I (R = H).

Their protective effect against triethyltin-induced brain edema is less than that of vinburnine. I (R = 3-chloro-1,2,5,6-tetrahydropyridinoacetyl) was most active.

IT 119154-72-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as protector agent against triethyltin-induced brain edema)

RN 119154-72-2 CAPLUS
 CN 4-Morpholineacetamide, N-[(3a,16a)-14,15-dihydro-14-oxoeburnamen-11-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.02

380.98

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.12

-3.12

STN INTERNATIONAL LOGOFF AT 07:38:33 ON 13 FEB 2007